p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation

被引:52
作者
Canitrot, Y
Falinski, R
Louat, T
Laurent, G
Cazaux, C
Hoffmann, JS
Lautier, D
Skorski, T
机构
[1] Temple Univ, Ctr Biotechnol, Philadelphia, PA 19122 USA
[2] Inst Pharmacol & Biol Struct, Toulouse, France
[3] Inst Claudius Regaud, INSERM, U563, Toulouse, France
[4] CHU Purpan, Hematol Serv, Toulouse, France
关键词
D O I
10.1182/blood-2002-10-3207
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Both clinical and experimental evidence illustrate that p190 and p210 BCR/ABL oncogenic tyrosine kinases induce resistance to DNA damage and confer an intrinsic genetic instability. Here, we investigated whether BCR/ABL expression could modulate nucleotide excision repair (NER). We found that ectopic expression of p210 BCR/ABL in murine lymphoid BaF3 cell line inhibited NER activity in vitro, promoting hypersensitivity of these cells to ultraviolet (UV) treatment and facilitating a mutator phenotype. How-ever, expression of p210 BCR/ABL in human and murine myeloid cell lines and primary bone marrow cells resulted in the increased NER activity and resistance to UV irradiation. The ABL tyrosine kinase inhibitor STI571 reversed these effects, showing that p210 BCR/ABL tyrosine kinase activity is responsible for deregulation of NER. Hypoactivity of NER in p210 BCR/ABL-positive lymphoid cells was accompanied by the decreased interaction between proliferating cell nuclear antigen (PCNA) and xeroderma pigmentosum group B (XPB); conversely, this interaction was enhanced in p210 BCR/ABL-positive myeloid cells. p190 BCR/ABL did not affect NER in lymphoid and myelold cells. In summary, our study suggests that p210 BCR/ABL reduced NER activity in lymphoid cells, leading to hypersensitivity to UV and mutagenesis. In contrast, p210 BCR/ABL expression in myeloid cells facilitated NER and induced resistance to UV. (C) 2003 by The American Society of Hematology.
引用
收藏
页码:2632 / 2637
页数:6
相关论文
共 57 条
[51]   The BCR-ABL oncoprotein potentially interacts with the xeroderma pigmentosum group B protein [J].
Takeda, N ;
Shibuya, M ;
Maru, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (01) :203-207
[52]   Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells [J].
Thiesing, JT ;
Ohno-Jones, S ;
Kolibaba, KS ;
Druker, BJ .
BLOOD, 2000, 96 (09) :3195-3199
[53]   Synergistic activity of the new ABL-specific tyrosine kinase inhibitor ST1571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells [J].
Topaly, J ;
Zeller, WJ ;
Fruehauf, S .
LEUKEMIA, 2001, 15 (03) :342-347
[54]   Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis [J].
van der Kuip, H ;
Goetz, AW ;
Miething, C ;
Duyster, J ;
Aulitzky, WE .
BLOOD, 2001, 98 (05) :1532-1541
[55]   COMPLEMENTATION OF THE XERODERMA PIGMENTOSUM DNA-REPAIR DEFECT IN CELL-FREE-EXTRACTS [J].
WOOD, RD ;
ROBINS, P ;
LINDAHL, T .
CELL, 1988, 53 (01) :97-106
[56]  
Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO
[57]  
2-A